(Q39028177)

English

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

scientific article published on 11 January 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 September 2017

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. (English)

1 reference

Europe PubMed Central

8 September 2017

1 reference

based on heuristic

inferred from title

Andreas Hochhaus

23

object named as

A Hochhaus

1 reference

Europe PubMed Central

8 September 2017

author name string

C Schütz

1

1 reference

Europe PubMed Central

8 September 2017

S Inselmann

2

1 reference

Europe PubMed Central

8 September 2017

S Sausslele

3

1 reference

Europe PubMed Central

8 September 2017

C T Dietz

4

1 reference

Europe PubMed Central

8 September 2017

M C Mu Ller

5

1 reference

Europe PubMed Central

8 September 2017

E Eigendorff

6

1 reference

Europe PubMed Central

8 September 2017

C A Brendel

7

1 reference

Europe PubMed Central

8 September 2017

S K Metzelder

8

1 reference

Europe PubMed Central

8 September 2017

T H Bru Mmendorf

9

1 reference

Europe PubMed Central

8 September 2017

C Waller

10

1 reference

Europe PubMed Central

8 September 2017

J Dengler

11

1 reference

Europe PubMed Central

8 September 2017

M E Goebeler

12

1 reference

Europe PubMed Central

8 September 2017

R Herbst

13

1 reference

Europe PubMed Central

8 September 2017

G Freunek

14

1 reference

Europe PubMed Central

8 September 2017

S Hanzel

15

1 reference

Europe PubMed Central

8 September 2017

T Illmer

16

1 reference

Europe PubMed Central

8 September 2017

Y Wang

17

1 reference

Europe PubMed Central

8 September 2017

T Lange

18

1 reference

Europe PubMed Central

8 September 2017

F Finkernagel

19

1 reference

Europe PubMed Central

8 September 2017

R Hehlmann

20

1 reference

Europe PubMed Central

8 September 2017

M Huber

21

1 reference

Europe PubMed Central

8 September 2017

A Neubauer

22

1 reference

Europe PubMed Central

8 September 2017

J Guilhot

24

1 reference

Europe PubMed Central

8 September 2017

F Xavier Mahon

25

1 reference

Europe PubMed Central

8 September 2017

M Pfirrmann

26

1 reference

Europe PubMed Central

8 September 2017

A Burchert

27

1 reference

Europe PubMed Central

8 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

11 January 2017

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

31

1 reference

Europe PubMed Central

8 September 2017

4

1 reference

Europe PubMed Central

8 September 2017

829-836

1 reference

Europe PubMed Central

8 September 2017

https://scigraph.springernature.com/pub.10.1038/leu.2017.9

0 references

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Standardized definitions of molecular response in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Harmonization of molecular monitoring of CML therapy in Europe

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Immunology and immunotherapy of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Regulation of antiviral T cell responses by type I interferons

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

The PD-1 pathway in tolerance and autoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Plasmacytoid dendritic cells mediate oral tolerance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Antigen-presentation properties of plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Dangers of using "optimal" cutpoints in the evaluation of prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

21 January 2018

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

7 January 2021

based on heuristic

inferred from DOI database lookup

Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2017.9

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28074067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML St

1 reference

https://pubmed.ncbi.nlm.nih.gov/28074067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28074067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa

1 reference

https://pubmed.ncbi.nlm.nih.gov/28074067

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/LEU.2017.9

1 reference

Europe PubMed Central

8 September 2017

1 reference

Europe PubMed Central

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39028177&oldid=1790298142"